Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2012-05-02

FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for FOCALIN XR by Sandoz Inc (dexmethylphenidate hydrochloride). The submission status indicates approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE)

Snippet

SUPPL AP for FOCALIN XR (DEXMETHYLPHENIDATE HYDROCHLORIDE)